NeuroPace (NPCE) Q3 2026 Earnings Call Transcript

NeuroPace reported Q3 2026 revenue of $23.1M, missing expectations. CEO Joel Becker attributed the shortfall to transient issues, including account-specific operational challenges and sales team transitions. The company revised full-year revenue guidance to $91M-$92M and expects 15% core RNS revenue growth in 2027, accelerating to 20% by year-end. CMS increased the hospital outpatient payment rate for RNS replacement procedures by 11% for 2027.

Original reporting
Published Nov 13, 2026, 5:43 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 5:50 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
NeuroPace (NPCE) Q3 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$NPCEBearishMed
01

Why it matters

The revised guidance and earnings miss are likely to trigger a sell‑off, but longer‑term catalysts could mitigate the downside.

02

Market read

First public disclosure of revised 2026 guidance for a micro‑cap medical‑device firm; immediate price impact expected.

03

What to watch

Potential upside from CMS reimbursement increase for RNS replacements and upcoming IGE indication approval.

Relevance 7/10Novelty 7/10Timing: post-earnings

Background

NeuroPace's Q3 earnings call highlighted operational issues, sales leadership changes, and exit from SEEG distribution, culminating in a revised revenue outlook.

Company-level read

Ticker impact

$NPCEBearishHigh confidence
Context

NeuroPace reported Q3 2026 revenue of $23.1M, missed expectations and revised full-year 2026 revenue guidance to $91M-$92M.

Expected impact

likely downside as investors price in weaker guidance and execution challenges

Evidence & confidence

The transcript provides the first public disclosure of revised 2026 guidance, a material change that typically moves the stock lower.

Market effects

May weigh on other neurotechnology and medical device stocks as investors reassess growth forecasts.

Limited to U.S. small-cap biotech/medical device segment.

Low; impact confined to niche sector.

Counterpoint

If the company can successfully expand its account base and launch new indications, the guidance cut may be temporary.

Key entities

  • NeuroPace

    Medical device maker of the RNS system for epilepsy.

  • CMS

    U.S. Centers for Medicare & Medicaid Services, released OPPS rule increasing replacement procedure payment.

Related articles

$NPCEHigh

Why is NeuroPace stock plummeting 40% today?

NeuroPace (NPCE) stock fell 38.3% to $7.42 after reporting Q3 2026 revenue of $23.1M, missing estimates of $27.1M. The company cut its full-year 2026 revenue outlook to $91–92M from $99.5–101.5M, citing sales force disruptions. Leerink downgraded NPCE to Market Perform with a $7 target, while KeyBanc reduced its target to $14. Insider selling and a rate-sensitive macro environment added to the decline.

$NPCEMed

What NeuroPace (NPCE) Said on Its Q3 Earnings Call

NeuroPace (NPCE) reduced its 2026 revenue guidance to $91M-$92M from $99.5M-$101.5M, citing delays at large accounts. Q4 procedure volumes show recovery signs. Adjusted gross margin forecast raised to 83%-83.5%, while operating expenses lowered to $85M-$86M. 2027 RNS revenue growth expected at 15%. FDA submissions for IGE and Remote Care feature are planned.

$NPCEMed

NeuroPace Reports Third Quarter 2026 Financial Results and Provides Revised Full Year Guidance

NeuroPace Inc (NPCE) filed an SEC Form 8-K — Results of Operations and Financial Condition. NeuroPace Reports Third Quarter 2026 Financial Results and Provides Revised Full Year Guidance Q3 2026 total revenue of $23.1 million, including $22.9 million in RNS revenue representing 1% growth Revises full year 2026 revenue guidance to $91 million to $92 million; focused on i